Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00058838 | Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease | PHASE3 | COMPLETED | 854 | — | — | Apr 1, 2003 | Sep 1, 2004 | Jun 7, 2006 | 134 | United States, Argentina +12 |
| NCT00036218 | Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease. | PHASE3 | COMPLETED | 600 | — | — | Dec 1, 2001 | Apr 1, 2003 | Jun 7, 2006 | 102 | United States, Argentina +2 |
| Name | Type | Description |
|---|---|---|
| sumanirole | DRUG | - |
| ropinirole | DRUG | - |
Inclusion Criteria: Idiopathic Parkinson's disease \< 7 years duration Modified Hoehn and Yahr Scale Stages I through III Age greater than or equal to 30 years old Patients or their partners must use adequate contraceptive methods Patients who are willing and able to comply with scheduled visit...